Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling

Blood

Volumn 121, Issue 10, 2013, Pages 1824-1838

  Zhang, Bin ^a   Li, Min ^a   McDonald, Tinisha ^a   Holyoake, Tessa L ^b   Moon, Randall T ^c   Campana, Dario ^d   Shultz, Leonard ^e   Bhatia, Ravi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD71 ANTIGEN; N CADHERIN RECEPTOR; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW; CANCER RESISTANCE; CANCER STEM CELL; CD34 SELECTION; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COCULTURE; COLONY FORMATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; DRUG EXPOSURE; ENGRAFTMENT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA STEM CELL; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84876543495     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412890     Document Type: Article

References (50)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330- 1340. (Pubitemid 29196596)
2. Druker BJ, Guilhot F, O'Brien SG, et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417. (Pubitemid 44903745)
3. Quint'as-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond -exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009;6(9):535-543.
4. Mahon FX, R'ea D, Guilhot J, et al. Intergroupe Français des Leuc'emies Mý eloǐdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
5. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118(20): 5565-5572.
6. Chu S, Holtz M, Gupta M, et al. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD341 cells. Blood. 2004;103(8):3167-3174. (Pubitemid 38451695)
7. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-4539. (Pubitemid 43801382)
8. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCRABL activity. J Clin Invest. 2011;121(1):396-409.
9. Konig H, Copland M, Chu S, et al. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008;68(23):9624-9633.
10. Scadden DT. The stem cell niche in health and leukemic disease. Best Pract Res Clin Haematol. 2007;20(1):19-27.
11. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114(6): 1150-1157.
12. Matsunaga T, Takemoto N, Sato T, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9(9):1158-1165. (Pubitemid 37173700)
13. van der Kuip H, Goetz AW, Miething C, et al. Adhesion to fibronectin selectively protects Bcr-Abl1 cells from DNA damage-induced apoptosis. Blood. 2001;98(5):1532-1541.
14. Zhang B, Groffen J, Heisterkamp N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia. 2007; 21(6):1189-1197. (Pubitemid 46831807)
15. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113(24): 6206-6214.
16. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167-1174. (Pubitemid 44527352)
17. Krause DS, Lazarides K, von Andrian UH, et al. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12(10):1175-1180. (Pubitemid 44527353)
18. Bewry NN, Nair RR, Emmons MF, et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther. 2008; 7(10):3169-3175.
19. Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol. 2007;136(2): 269-275. (Pubitemid 46020754)
20. Jin L, Tabe Y, Konoplev S, et al. CXCR4 upregulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther. 2008;7(1): 48-58.
21. Nair RR, Tolentino JH, Argilagos RF, et al. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res. 2012;36(6):756-763.
22. Traer E, MacKenzie R, Snead J, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia. 2012;26(5):1140-1143.
23. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960):836-841. (Pubitemid 37351467)
24. Zhi L, Wang M, Rao Q, et al. Enrichment of N-Cadherin and Tie2-bearing CD341/CD38-/CD1231 leukemic stem cells by chemotherapyresistance. Cancer Lett. 2010;296(1):65-73.
25. Kiel MJ, Acar M, Radice GL, et al. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell. 2009; 4(2):170-179.
26. Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell. 2007;1(2): 204-217. (Pubitemid 47215590)
27. Wein F, Pietsch L, Saffrich R, et al. N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res (Amst). 2010;4(2):129-139.
28. Abe K, Takeichi M. EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc Natl Acad Sci USA. 2008;105(1):13-19.
29. Nygren MK, Døsen-Dahl G, Stubberud H, et al. beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp Hematol. 2009;37(2): 225-233.
30. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009; 10(7):468-477.
31. Malhotra S, Kincade PW. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell. 2009;4(1):27-36.
32. Minami Y, Stuart SA, Ikawa T, et al. BCR-ABLtransformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA. 2008;105(46): 17967-17972.
33. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657-667. (Pubitemid 39063268)
34. Zhao C, Blum J, Chen A, et al. Loss of betacatenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12(6): 528-541. (Pubitemid 350199070)
35. Hu Y, Chen Y, Douglas L, et al. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia. 2009;23(1):109-116.
36. Heidel FH, Bullinger L, Feng Z, et al. Genetic and pharmacologic inhibition of b-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell. 2012;10(4):412-424.
37. Coluccia AM, Vacca A, Dunǎch M, et al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007;26(5):1456-1466. (Pubitemid 46398694)
38. Samanta AK, Lin H, Sun T, et al. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468-6472. (Pubitemid 44085597)
39. Williams E, Williams G, Gour BJ, et al. A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif. J Biol Chem. 2000; 275(6):4007-4012. (Pubitemid 30094629)
40. Biechele TL, Moon RT. Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs. Methods Mol Biol. 2008;468:99-110.
41. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550. (Pubitemid 41528093)
42. Moeller SJ, Head ED, Sheaff RJ. p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. Mol Cell Biol. 2003;23(11): 3735-3752. (Pubitemid 36597455)
43. Sǒderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3(12):995-1000. (Pubitemid 44782698)
44. Mihara K, Imai C, Coustan-Smith E, et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol. 2003;120(5):846-849. (Pubitemid 36315109)
45. Chalpe AJ, Prasad M, Henke AJ, et al. Regulation of cadherin expression in the chicken neural crest by the Wnt/b-catenin signaling pathway. Cell Adhes Migr. 2010;4(3):431-438.
46. Troyanovsky RB, Laur O, Troyanovsky SM. Stable and unstable cadherin dimers: mechanisms of formation and roles in cell adhesion. Mol Biol Cell. 2007;18(11):4343-4352. (Pubitemid 350060163)
47. Haug JS, He XC, Grindley JC, et al. N-cadherin expression level distinguishes reserved versus primed states of hematopoietic stem cells. Cell Stem Cell. 2008;2(4):367-379. (Pubitemid 351455240)
48. Jamora C, DasGupta R, Kocieniewski P, et al. Links between signal transduction, transcription and adhesion in epithelial bud development. Nature. 2003;422(6929):317-322. (Pubitemid 36378359)
49. Nelson WJ, Nusse R. Convergence of Wnt, betacatenin, and cadherin pathways. Science. 2004; 303(5663):1483-1487. (Pubitemid 38314410)
50. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by upregulation of anti-apoptotic proteins. Leukemia. 2002;16(9):1713-1724.